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Hsp70s are important cancer chaperones that act
upstream of Hsp90 and exhibit independent anti-
apoptotic activities. To develop chemical tools for
the study of human Hsp70, we developed a homol-
ogy model that unveils a previously unknown allo-
steric site located in the nucleotide binding domain
of Hsp70. Combining structure-based design and
phenotypic testing, we discovered a previously un-
known inhibitor of this site, YK5. In cancer cells,
this compound is a potent and selective binder of
the cytosolic but not the organellar human Hsp70s
and has biological activity partly by interfering with
the formation of active oncogenic Hsp70/Hsp90/
client protein complexes. YK5 is a small molecule
inhibitor rationally designed to interact with an allo-
steric pocket of Hsp70 and represents a previously
unknown chemical tool to investigate cellular mech-
anisms associated with Hsp70.
INTRODUCTION
The 70 kDa heat shock proteins (Hsp70s) are ubiquitously found
in many different species and are central components of the
cellular network of molecular chaperones (Mayer and Bukau,
2005). In humans, there are at least 13 isoforms of Hsp70 located
in all major cellular compartments, among which are two major
cytoplasmic forms, the constitutive heat shock cognate 70
(Hsc70) and the inducible Hsp70 (Daugaard et al., 2007).
Hsp70s are important regulators of the apoptotic machinery,
including the apoptosome, the caspase activation complex,
and apoptosis-inducing factor (AIF), and play a role in the protea-Chemistry & Biology 20, 1469–148some-mediated degradation of apoptosis-regulating proteins.
Hsp70s also participate in oncogenesis, as suggested by
their constituency in the Hsp90 super-chaperone machinery,
whereby the HSP-organizing protein (HOP) co-chaperone
bridges the Hsp70 and the Hsp90 systems (Brodsky and Chio-
sis, 2006; Powers et al., 2010; Re´role et al., 2011). Thus, the
downregulation or selective inhibition of Hsp70smight constitute
a valuable strategy for the treatment of cancer, and be especially
effective in overcoming tumor cell resistance (Brodsky and Chio-
sis, 2006; Patury et al., 2009; Powers et al., 2010; Re´role et al.,
2011). Considering the importance of Hsp70 as a potential ther-
apeutic target, several efforts centered on the discovery of small
molecule Hsp70 inhibitors; however, only a limited number of
molecules are available (Patury et al., 2009; Powers et al.,
2010; Re´role et al., 2011).
The human Hsp70 (hHsp70) chaperones, Hsp70 and Hsc70,
are composed of two major domains: an 45 kDa, nucleotide
binding domain (NBD) that contains the regulatory ATP/ADP
binding pocket and an 25 kDa substrate binding domain
(SBD) joined together by a flexible linker (Mayer and Bukau,
2005). Nucleotide binding and hydrolysis and communication
between the two domains are essential for Hsp70 molecular
chaperone activity; thus, it is not surprising that the few known
Hsp70 modulators interfere either with nucleotide binding
and/or with the conformational motility of the protein. A few
of these compounds, such as 15-deoxyspergualin, pifithrin-m
(2-phenylethynesulfonamide), a small molecular weight peptide
(NRLLLTG), and fatty acid acyl benzamides, are believed to
bind to the SBD of Hsp70 while dihydropyrimidines and myrice-
tin to its NBD (Haney et al., 2009; Patury et al., 2009; Powers
et al., 2010; Re´role et al., 2011). However, little, if any, structural
information on these complexes is available. Recently, adeno-
sine-based analogs were designed to bind within the ATPase
pocket of Hsp70 (Williamson et al., 2009). All of these com-
pounds have been used in cellular models of disease to investi-
gate mechanisms associated with Hsp70, in spite of their low0, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1469
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(Powers et al., 2010; Re´role et al., 2011), underscoring the
need for better Hsp70 inhibitor-based chemical tools.
Our preferred approach for the identification of small molecule
inhibitors is one that combines structure-based design with
phenotypic assays (Chiosis et al., 2001; He et al., 2006). For
Hsp70 however, although several high-resolution crystal and
solution structures are available for Hsp70s of several species
(Flaherty et al., 1994; Kityk et al., 2012; Sriram et al., 1997; Wis-
niewska et al., 2010; Worrall and Walkinshaw, 2007; Zhu et al.,
1996), a crystal structure of a functionally intact hHsp70 chap-
erone containing both NBD and SBD has not been resolved.
Furthermore, while several crystal structures are available for
the human NBD, most capture it in a relatively closed conforma-
tion (Sriram et al., 1997; Wisniewska et al., 2010). In contrast,
recent nuclear magnetic resonance (NMR) techniques and
molecular dynamics studies suggest considerable flexibility
and rearrangements in this domain with the cleft opening upon
ADP binding (Bhattacharya et al., 2009; Woo et al., 2009). Thus
for flexible proteins such as Hsp70, where ligand binding
pockets are influenced by global protein conformational
changes, X-ray structures may not properly capture all poten-
tially available ligand binding sites.
We here build a theoretical model for hHsp70 that allows for
the discovery of a druggable allosteric pocket and the rational
design of small molecules that selectively occupy this pocket.
We demonstrate that the identified small molecules inhibit the
biological functions of human Hsp70 in cells and are valuable
tools for parsing out mechanisms associated with Hsp70.
RESULTS AND DISCUSSION
Modeling Leads to a Structure of Full-Length Human
Hsp70
Lacking a structure of hHsp70 optimal for our ligand discovery
efforts, we first sought to construct a homologymodel (a theoret-
ical three-dimensional structure) for full-length hHsp70 that
captures the conformational flexibility of the protein. The most
important factors in homology model construction are correct-
ness of alignment and the choice of template structures (Wallner
and Elofsson, 2005). The N-terminal crystal structure of the
hHsp70 protein (Protein Data Bank [PDB] ID: 1S3X; Sriram
et al., 1997) was the best available template for the amino acids
in this region of Hsp70 (Met1-Gly382, hHsp70). No crystal struc-
ture was available for the hHsp70 SBD, therefore the Escherichia
coli Hsp70 (DnaK) structure (PDB ID: 2KHO; Bertelsen et al.,
2009), a protein that shares a 62% similarity with hHsp70, was
selected as a template for modeling a segment of the SBD
(Asp385-Gln538, E. coli.; Asp383-Ala541, hHsp70). Finally,
the crystal structure of Caenorhabditis elegans Hsp70 (PDB
ID: 2P32; Worrall andWalkinshaw, 2007) was used as a template
for the C terminus (Leu543-Ser614, C. elegans; Leu542-Gly613,
hHsp70). The extreme C-terminal amino acids (614–641) of
hHsp70 did not have a template structure, and hence were not
modeled. After template selection, alignment of the template
and the ability to detect the structural similarities based on the
amino acid sequence, determine the overall quality of the model.
For closely related protein sequences with high similarity, the
alignment ismost often optimal. In our study, 606 of 613 residues1470 Chemistry & Biology 20, 1469–1480, December 19, 2013 ª2013were identical to the three implemented templates (PDB ID:
1S3X, 2KHO, and 2P32), indicating optimal alignment (Fig-
ure S1A available online). Following alignment of the residue
side chains, amino acids missing in the template structure
(PDB ID: 2KHO), such as Lys384, Ser385, Glu386, Asn387,
and Arg509 (hHsp70), were successfully inserted using a semi-
automated procedure in Prime. The model thus obtained con-
tained loops based on the template structure (excluding termini).
All the loop regions (33 loops) were optimized using the loop
refinement tool in Prime to generate proper conformations for
loops. Finally, the obtained protein model was subjected to a
protein preparation utility, followed by rigorous energy minimiza-
tion to relax unfavorable contacts. Superimposition of the back-
bone atoms in the NBD of the homology model and the template
structure (PDB ID: 1S3X) gave a root-mean-square deviation
of 1.01 A˚ and a good alignment score of 0.05 (smaller is better,
more than one poor alignment), validating our model (Fig-
ure S1B). The homology model thus contained 613 amino acid
residues and had two major domains, an NBD and an SBD,
joined together by a flexible linker (Figure 1A). The N-terminal
ATPase domain displayed an actin-like hexokinase fold and
had two globular lobes, I (subdomains IA and IB) and II (subdo-
mains IIA and IIB). Twelve a helices and 16 b sheets compiled
the NBD, which corroborates with the crystal structure of
the NBD (Sriram et al., 1997). The C-terminal SBD contained
two functionally relevant subdomains; a sandwich of two four-
stranded b sheets containing the peptide binding subdomain
(SBD-b) and a four a helix subdomain (SBD-a), also called the
lid domain (Zhu et al., 1996).
This nucleotide-free structure of hHsp70 was then superim-
posed with approximately 25 structures of Hsp70 resolved by
crystallography. These were resolved for Hsp70 paralogs from
different species, including the human protein, and captured
the protein in the apo-, the ATP-, or the ADP-bound state
(http://www.rcsb.org). Our model most closely resembles that
of the ADP-boundHsp70,with the distinction that themodel cap-
tures the N-terminal binding cleft in a conformation that is more
open than that seen in the X-ray determined structure (Figures
S1B and S1C). As indicated by NMR techniques and molecular
dynamics, Hsp70 is a flexible protein in which several residues
rotate and move substantially during chaperone cycling. During
these conformational movements, several energetically favored
minima are possible. The energy minimization simulation proto-
col that we used in creating the homology model sampled
several such possible dynamic conformations and identified the
captured conformation, energetically as a preferred conforma-
tion. Crystal structures also capture a specific energetic
minimum,which, possibly influenced by the crystallization condi-
tions, differs from that captured by our computations, providing
a possible explanation to the differences in Hsp70 structure
captured by crystallography and the computational modeling.
Modeling Unveils Five Druggable Sites in hHsp70
The quality of any homology model depends on the force field
and the sampling procedure. Although Prime, the software
used in our simulations, uses an improved energy model (Li
et al., 2011), our derived structure may, nonetheless, deviate
from the native structure at any location in the protein. In spite
of these potential limitations, we used the theoretical model toElsevier Ltd All rights reserved
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Figure 1. Building of the hHsp70 Homology Model and Evaluation of the Potential Druggable Sites
(A) Secondary structure of the homology model of hHsp70. The position and geometry of various ‘‘sites’’ generated by SiteMap on the hHsp70 homology model
are shown.
(B) Characteristics of the five binding sites as calculated by SiteMap and Glide docking.
(C) Hydrophobic/hydrophilic maps of site 1 and site 2 are shown as determined by SiteMap. Hydrophobic, hydrogen bond donor, and hydrogen bond acceptor
maps are shown in yellow, blue, and red, respectively. For clarity, only the N-terminal region of hHsp70 homology model is displayed.
See also Figure S1.
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This software considers several physical descriptors such as
size, degree of enclosure/exposure, tightness, van der Waals
forces, hydrophobic/hydrophilic character, and hydrogen-
bonding possibilities to find potential ligand-binding pockets. It
does so by linking together site points that are most likely to
contribute to protein/ligand or protein/protein interaction. After
it examines the entire structure, it then ranks the sites. The size
of the site (measured by the number of found site points), the
relative openness of the site (measured by the exposure and
enclosure properties), and tightness of the site (measured by
the contact term and the hydrophobic and hydrophilic character
of the site) contribute significantly toward ranking. The top five
sites scored by SiteMap had a Site-score (S-score) of 0.80 or
higher (Figure 1B) and thus these could be plausible ligand-bind-
ing sites (Halgren, 2009). Other sites, scoring lower than 0.8,
such as those on the protein surfaces, were potential artifacts
of the computational model and eliminated from further analysis.
In addition to the S-score, we also measured in SiteMap the
druggability of the site, as described by the D-score (Figure 1B).
The D-score includes terms that promote ligand binding, such
as adequate size and isolation from solvents, but offsets them
with a term that penalizes increasing hydrophilicity. With use ofChemistry & Biology 20, 1469–148the D-score criteria, sites are classified into undruggable, difficult
to drug, and druggable (Halgren, 2009). Undruggable sites are
strongly hydrophilic, relatively smaller in size, with little or no
hydrophobic character, and are characterized by a D-score value
lower than 0.83 (site 5, Figure 1B). Difficult sites are sufficiently hy-
drophilic to require administration as a prodrug, but they are less
hydrophobic than a typical binding site and are defined by a
D-score value between 0.83 and 0.98 (sites 2–4, Figure 1B). Drug-
gable sites are of a size, enclosure, hydrophobicity, and hydrophi-
licity to favorably accommodate a small molecule ligand, and,
moreover, holdaD-score valuehigher than0.98 (site 1, Figure1B).
Among the best five predicted sites, sites 3, 4, and 5 had a
limited number of site points (described by size in Figure 1B),
the cavity was small and the site shallow (Figure 1A). As a result,
it is more difficult to generate sufficient binding affinity for these
sites. Site 2, including the groove occupied by the endogenous
ligands ATP and ADP, had a favorable size (site points: 178; Fig-
ure 1B) and S-score (1.12; Figure 1B). On closer inspection, site 2
mainly consisted of hydrophilic amino acids (Figure 1C). In
the absence of suitable regions for hydrophobic interactions, it
was potentiallymore difficult to target, as depicted by its D-score
(0.91, Figure 1B). This site is also conserved in the actin fold fam-
ily of ATPases that consists of Hsp70, actin, and sugar kinases,0, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1471
Figure 2. Design of Site 1 Interacting Small
Molecules and Computational Validation of
Their Binding Mode
(A) General structure of the 2,50-thiodipyrimidine
scaffold and of the lead derivative, YK5, designed
to properly fit into site 1 (yellow surface). The com-
pounds also incorporate the acrylamide group for
potential interaction with Cys267 located in site 1.
(B) Surface model representation of the best
Glide-predicted binding pose derived for com-
pound YK5 within the allosteric site 1.
See also Figures S1 and S2.
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between these proteins (Sriram et al., 1997), altogether rendering
this pocket less desirable for ligand design.
HomologyModel Unveils a Drugabble Site Not Evident in
X-Ray Structures
Site 1, located in a cleft region outside the ATP/ADP binding
domain (Figure 1A) and flanked by subregions IB and IIB, was
larger in size (site points: 385; Figure 1B), had a larger groove
and consisted of hydrophilic and hydrophobic amino acids, sug-
gesting this site as most druggable on hHsp70 (D-score: 1.00;
S-score: 1.05; Figure 1B). Hydrophobic/hydrophilic maps also
indicated site 1 to be of a favorable character for ligand design
being lined by a balanced number of hydrophilic and hydropho-
bic residues, such as Tyr41, Val59, Phe68, Asp69, His89, Pro91,
Glu231, Asp234, Val238, Val260, Arg261, Leu263, and Arg264
(numbering as in human Hsp70) (Figure 1C).
As indicated above, the several available crystal structures
of Hsp70 capture the nucleotide binding domain in a relatively
closed conformation. Concordantly, a SiteMap analysis con-
ducted on the X-ray structure of Hsp70 (PDB ID: 1S3X) indicated
a smaller cavity for the allosteric site1 (Figures S1B and S1C),
specifically of only 138 site points as compared to 385 site points
in the homology model.
On further analysis, we noted that site 1 also contained
a potentially reactive cysteine residue located at the base of
the cavity (Figures 1A, S1B, and S1C; Cys267). Interestingly,
whereas this Cys is captured in all available crystal structures
buried inside the protein (Figures S1B and S1C), evidence sug-
gests that conformational changes in Hsp70 that expose this
residue do occur in the native protein (Liu et al., 1996; Miyata
et al., 2012).
Taking together the S- and D-scores, its size, its balanced
hydrophobic and hydrophilic character, exposure and enclosure
properties, site 1 was predicted to be the most druggable cavity
in Hsp70, and thus we focused on this allosteric site 1 for further
design of Hsp70 inhibitors.1472 Chemistry & Biology 20, 1469–1480, December 19, 2013 ª2013 Elsevier Ltd All rights reRational Design Identifies
Previously Unknown Allosteric Site
Binders
Upon analysis of the size and geometry of
site 1 (Figure 2A), we mentally designed
several scaffolds that we predicted would
adopt a proper conformation and would
favorably interact with the allosteric struc-tural groove of hHsp70 (Kang et al., 2012). We then positioned
the acrylamide at one end of the molecule where it could form
a potential covalent bond between the inhibitor and Cys267.
Due to the location of Cys267 deep inside the cavity (Figures
S1B and S1C), such bond formation would be possible only after
the ligand inserted into the pocket and achieved a proper fit. By
gaining affinity through a covalent linkage in addition to enthalpy,
one can increase the ligand’s apparent affinity for the protein
even when its fit is less than optimal. Thus, the use of this tech-
nique for early stage ligand design offers advantages, especially
when the architecture of the binding pocket, as captured by the
homology model may not entirely capture the native pocket. We
reasoned that once a proper scaffold for this pocket was identi-
fied, we could improve the enthalpy of binding throughmedicinal
chemistry efforts, eliminating the need for the covalent bond.
With this method, we designed and synthesized several
scaffolds, one being based on 2,50-thiodipyrimidines (termed
YK-class, Figure 2A). It is noteworthy that these compounds
are of a chemical space yet little explored by either nature or
man. From these efforts, we identified a lead compound, YK5
that we will analyze here.
Computational Analysis Predicts Favorable Binding of
YK5 to Hsp70
To investigate the binding of YK5 to Hsp70, we first performed a
computational analysis. Binding interactions, compound orienta-
tion (Figure 2B), and G-score values concluded that YK5 bound
most favorably intosite1.Thebestbindingmodederivedbydock-
ing of YK5 onto site 1 showed the piperazine (ring A) pointing to-
ward the exit and the acrylamide toward the bottom of the pocket
(Figure 2B). Modeling predicted several favorable interactions be-
tween site 1 and YK5 (Figure S2A). Specifically, the alkene group
of the acrylamide moiety was favorably placed to form a covalent
adductwith Cys267 (distance of 2.6 A˚ between the alkene and the
sulfur) and to establish hydrophobic interactions with Leu237 and
Val238 (3 A˚). Other interactions of the acrylamide and surround-
ing residues (i.e., Arg264,Glu268) are also possible. The 6-NH2 onserved
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Figure 3. YK5 Interacts Selectively with the Cytosolic Hsp70 and Hsc70 through the Allosteric Site 1
(A) Cancer cells were treated with the indicated concentrations of YK5-biotin (YK5B) for 6 hr prior to lysing and precipitation of protein complexes on streptavidin
beads. Beads were washedwith high-salt (1MNaCl) buffer, proteins eluted by boiling in 2%SDS, separated on a denaturing gel, and silver stained. BB70 Ab pull-
downs were used to indicate the position of Hsp70s (BB70 IP). This antibody recognizes Hsp70, Hsc70, Grp75, and Grp78. This experiment was repeated twice
with comparable results.
(B) Cancer cells were treated for 24 hr with the indicated concentrations of YK5 and cells were lysed. Protein complexes were isolated through chemical pre-
cipitation by incubating the cell extract with YK5B-beads, eluted with 2%SDS, separated on a denaturing gel, and depicted as indicated.
(C) Protein complexes from cancer cell extracts were isolated through chemical precipitation with YK5B-beads or an inert molecule, D-biotin. Proteins were then
separated on a denaturing gel and analyzed with western blot (WB). This experiment was repeated twice with comparable results.
(D) Cancer cells were treated for the indicated times with YK5B, prior to lysing and precipitation of protein complexes on streptavidin beads. Beads were washed
with high-salt buffer, proteins eluted by boiling in 2% SDS, separated on a denaturing gel, and silver stained.
(E) The experimental set-up was similar to that in (A), but proteins were analyzed with WB.
(F) Experiment set-up as in (A) for cancer cells transfected with FLAG-tagged Hsc70-wild-type or Hsc70-C267S and incubated with YK5B for 4 hr. Beads were
washed with high salt/high detergent (RIPA with 1M NaCl) before WB analysis. The amount of Hsc70 remaining on the YK5B-beads was quantified and then
plotted against the concentration of YK5B. Data are presented as mean ± SD (n = 5). A representative WB is also shown (right).
See also Figures S3–S5.
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Inactivating Hsp70 via an Allosteric PocketringC is poised for ionic interactionswith the carboxylate group of
Asp234andGlu268,whereas ringCmaybe stabilizedbycation-p
interactionswith the guanidine group of Arg264. The piperazine of
YK5 ispoised to formhydrogenbondswith thebackbone -C=Oof
His89.Wealsodesignedanegativecontrol compound,YK20 (Fig-
ure S2B), to use for further testing.
Biochemical Analyses Validate that YK5 Interacts
Selectively with Hsp70
To experimentally confirm our computational prediction that YK5
interacted with hHsp70 at the allosteric site, we designed a bio-Chemistry & Biology 20, 1469–148tinylated YK5 derivative, YK5-biotin (YK5B; Kang et al., 2012).
The addition of YK5B (Figure 3A) but not of D-biotin to cancer
cells, followed by isolation of complexes on streptavidin beads
and washing of beads with high-salt buffer, identified a major
band around 70 kDa, which was competed off in a dose-depen-
dent manner by cell pretreatment with soluble YK5 (Figure 3B).
We used an anti-Hsp70 antibody BB70 as a positive control
(Figure 3A; BB70 IP).
There are at least eight highly homologous Hsp70 family
members, including the constitutively expressed Hsc70, several
inducible forms including Hsp70-1 and Hsp70-6, all mainly0, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1473
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plasmic reticulum forms, Grp75 and Grp78, respectively
(Daugaard et al., 2007). Liquid chromatography-tandem mass
spectroscopy (LC/MS-MS) analysis of peptide digests obtained
from the YK5B-isolated band confirmed the presence of
two inducible Hsp70 isoforms (Hsp70-1 and Hsp70-6), and of
Hsc70, the constitutive Hsp70 member (Hsp70-8; Table S1A),
all three cytosolic Hsp70 members. Their identity was further
investigated by western blot, to demonstrate Hsc70 and
Hsp70 but not the unrelated chaperone, Hsp90, in the YK5B-
pulldowns (Figure 3C).
Together these findings confirm that, when exposed to a com-
plex protein mixture such as that present in the cancer cell, YK5
selectively and tightly binds to the cytosolic Hsp70s.
YK5 Interacts with the Allosteric Site 1 of Hsp70
Wenext demonstrated interaction of YK5with the allosteric site 1
and potential covalent bond formation between YK5 and Hsp70
upon binding. For compounds where irreversible binding plays
a role, the half-maximal inhibitory concentration (IC50) consists
of two components, one reflecting reversible binding and another
reflecting the subsequent covalent binding, and depends on the
extent to which the covalent interaction has occurred. Indeed,
incubation of cells for 1–4 hours with YK5B but not D-biotin led
to a progressive increase in the amount of immobilized 70 kDa
band (Figure 3D), which by anti-biotin and Hsp70 immunoblots
(Figure 3E), was suggested to be an YK5B-Hsp70-containing
species. Weak to no interaction of YK5B with Grp75 and
Grp78, the mitochondrial and the endoplasmic reticulum Hsp70
family members, respectively, was detected under these condi-
tions by silver stain (Figure 3D) and immunoblot (Figure 3E),
confirming the LC/MS-MS findings (Table S1A).
Elution of protein complexes from the YK5B-beads in condi-
tions sufficiently harsh to disrupt the tightest known noncovalent
binding, the streptavidin-biotin complex (Ro¨sli et al., 2008),
confirmed that a covalently bound YK5-Hsp70 species was
formed when cells were incubated with YK5 (Figure S3). Trypsin
digestion of the YK5B-bound Hsp70s species, but not of BB70
antibody pulldowns, identified a major m/z peak at 1867.915
atomic mass units that corresponds to YK5B attached to
LRTAC267ERAK (Figure S4). No labeling of these peptides
was observed when YK5B-Hsp70 isolates were reduced and
nonspecifically alkylated on remaining cysteines using beta-
mercaptoethanol and acrylamide, respectively (Table S1B).
The TACERAK sequence is conserved in human cytosolic
Hsp70s, but divergent in Grp75 and Grp78 (Figure S5), consis-
tent with their lack of interaction with YK5B under similar condi-
tions (Figures 3D and 3E; Table S1). Furthermore, high salt, high
detergent conditions eluted preferentially the Hsc70-C267S
protein over the WT form from preformed Hsc70/YK5B com-
plexes (Figure 3F).
Collectively, these data confirm interaction of YK5 with site 1,
as predicted by molecular modeling. They also indicate that the
interaction of YK5 with Hsp70 and Hsc70 consists of two ele-
ments, one reflecting reversible binding of favorable enthalpy
and another subsequent covalent cysteine modification. There
is precedent for the use of an acrylamide ‘‘warhead’’ in the devel-
opment of irreversible inhibitors for kinases (i.e., epidermal
growth factor receptor [EGFR], receptor tyrosine-protein kinase1474 Chemistry & Biology 20, 1469–1480, December 19, 2013 ª2013erbB-2 and -4 [HER2 and HER4], and B cell progenitor kinase),
that like Hsp70s, contain a reactive cysteine in their regulatory
site. These inhibitors, such as neratinib, dacomitinib, afatinib,
and PCI-32765, are in advanced clinical trials for cancer (Singh
et al., 2011).
YK5 Inhibits the Biochemical Functions of Hsp70
Next, we investigated whether binding of YK5 to Hsp70 inter-
fered with its main biochemical activities, specifically refolding
of a denatured client protein and its ATPase activity (Figure 4).
Hsp70 activities are stimulated by Hsp40 proteins and nucleo-
tide exchange factors, such as Hsp110 (Mayer and Bukau,
2005; Wegele et al., 2004; Young et al., 2004). Humans have
several cytosolic Hsp40s, including Hdj1, DJA1, DJA2, and
DJA4, and we have recently reported that DJA1 provides the
strongest stimulation of Hsc70 ATPase activity, whereas DJA2
is most efficient in promoting the refolding of an Hsc70/Hsp70
polypeptide substrate, firefly luciferase (Baaklini et al., 2012;
Bhangoo et al., 2007; Tzankov et al., 2008).
YK5 dose-dependently inhibited the refolding of luciferase by
purified Hsc70 and DJA2 (Figure 4A). In cells, the refolding of
heat-denatured luciferase by endogenous as well as transfected
Hsp70 was inhibited by YK5. The nonspecific capacity of trans-
fected Hsp70 to maintain substrate solubility after heat shock
was not greatly affected, indicating that YK5 targeted the spe-
cific substrate folding activity of Hsp70 (Figure 4B). YK5 also
inhibited Hsc70, whereas Hsp70-C267S gained resistance (Fig-
ure 4B). YK5 had no effect on the DJA1-stimulated ATPase rate
of recombinant Hsc70, and only partially inhibited the ATPase
rate stimulated by DJA1 and Hsp110 (Figure 4C). Because the
YK5 binding site does not overlap with that of ATP, its effect
probably results from disruption of the coordination of the N-
and C-terminal domains essential for chaperone function. The
modest defect in nucleotide exchange assisted by Hsp110
may be a secondary effect of disrupted coordination. In the
in vitro reconstituted systems, the core biochemical functions
of Hsp70 were inhibited by YK5 in assay conditions that do not
favor covalent bond formation, further indicating, in addition to
covalent reactivity, an appropriate fit for YK5 in the active site
of the target, as computationally predicted. Indeed, subsequent
medicinal chemistry on YK5 resulted in reversible Hsc70 and
Hsp70 binders of low nanomolar activity (Kang et al., 2012 and
G.C., unpublished data).
YK5 Inhibits the Functions of Hsp70 in Cancer Cells
Having demonstrated that YK5 is a specific Hsp70s interactor
and because Hsp70s are important regulators of Hsp90 tumor
activity (Moulick et al., 2011; Workman et al., 2007), we next
investigated if YK5 inhibited the Hsp70/Hsp90-pathway in can-
cer cells. Hsp90 in concert with Hsc70, the constitutive and
Hsp70, the inducible Hsp70 isoforms, maintains the transform-
ing capacity of several oncoproteins, including HER2, Akt,
Raf-1, insulin-like growth factor-I receptor, and hypoxia-induc-
ible factor 1; Brodsky and Chiosis 2006; Daugaard et al., 2007;
Re´role et al., 2011; Workman et al., 2007).
As evidenced in the SKBr3 breast cancer cells, YK5, but not
the negative control derivative YK20, induced the degradation
of HER2, Raf-1, and Akt kinases (Figure 5A), all three of which
are known Hsp90/Hsp70 complex onco-client proteins in thisElsevier Ltd All rights reserved
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Figure 4. YK5 Inhibits the Core Biochemical Functions of hHsp70
(A) Refolding of guanidinium-HCl denatured luciferase by Hsc70 and DJA2 at 30C was measured for the indicated times in the presence of YK5 (100 mM) or
vehicle (above), or at 60min in the presence of indicated concentrations of YK5 (below). In this and all graphs, errors bars represent SDs from themean of multiple
independent experiments (nR 4), *p < 0.05, **p < 0.01, ***p < 0.001.
(B) HEK293 cells were transfected with luciferase and either control vector, Hsp70, Hsp70-C267S, or Hsc70. The cells were treatedwith cycloheximide and either
vehicle or YK5 at 10 mM unless otherwise indicated, incubated at 45C for 1 hr, and allowed to recover at 37C for 2 hr (left). Cells were lysed during and after
refolding, and soluble HA-tagged luciferase and chaperones were detected in the lysates; exogenous transfected Flag-tagged Hsp70 and Hsc70 are visible as
bands above endogenous Hsp70 and Hsc70 (right). Luciferase enzymatic activities in the lysates were measured at 2 hr of refolding, unless otherwise indicated,
and represented as percentages of the initial activity before heat shock (below). YK5 inhibited endogenous Hsp70, and transfected Hsp70 and Hsc70, p < 0.001,
p < 0.001, and p = 0.0018, respectively, in multiple experiments (nR 5). The YK5 IC50 for luciferase refolding in cells is 7 mM. The activity of Hsp70 was not
significantly different from that of Hsp70-C267S (p = 0.315), but Hsp70-C267S was less inhibited by YK5 relative to wild-type (p < 0.001).
(C) Hsc70 ATPase rates were measured for reactions at 30Cwith the indicated combinations of Hsc70 and co-chaperones in the presence of vehicle (DMSO) or
YK5 (100 mM). ADP production wasmonitored with thin-layer chromatography separation of radiolabeled ADP from ATP and phosphorimaging analysis. YK5 had
little effect on the basal Hsc70 ATPase rate or the DJA1-stimulated rate but inhibited the DJA1- and Hsp110-stimulated rate, p = 0.081, 0.587 and p < 0.001,
respectively.
See also Figure S6.
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Inactivating Hsp70 via an Allosteric Pocketcellular context (Chiosis et al., 2001). Furthermore, the nononco-
genic tyrosine-protein kinase CSK, a c-Src related tyrosine
kinase, remained unaffected by the YK-agents and the direct
Hsp90 inhibitor PU-H71 (He et al., 2006; Figure 5A). YK5 also
induced apoptosis in these cells as evidenced by PARP cleav-
age (Figure 5A; cPARP).
These effects were not mediated by direct Hsp90 inhibition.
Only inhibitors of Hsp90 such as PU-H71 and PU24FCl (VilenchikChemistry & Biology 20, 1469–148et al., 2004), but not YK5, competed with a fluorescently labeled
Hsp90 ligand, GM-Cy3B (Moulick et al., 2006), for Hsp90 binding
(Figure 5B). Moreover, YK5B failed to bind Hsp90 in experi-
mental conditions it substantially isolated Hsp70 from cancer
cells extracts (Figure 3C).
In the SKBr3 breast cancer cells, degradation of Hsp90/
Hsp70-onco-client proteins by YK5 occurred at the increasing
low micromolar concentrations that also led to inhibition of cell0, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1475
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Figure 5. YK5 Inhibits hHsp70 Functions in
Cancer Cells
(A) Cancer cells were treated for 24 hr with vehicle
(DMSO) or the indicated concentrations of in-
hibitors and cells were lysed for WB analysis.
b-actin was used as loading control. The data are
consistent with those obtained from multiple
repeat experiments (n R 3). YK20, negative con-
trol; PU-H71, Hsp90 inhibitor.
(B) The ability of the indicated inhibitors to
compete with GM-Cy3B for Hsp90 binding in
cancer cell extracts was examined by fluores-
cence polarization. Values recorded in wells with
added inhibitor were normalized to values read in
control wells and plotted against the concentration
of tested inhibitor. Drugs were assayed in tripli-
cate. All compounds were used as DMSO stocks.
Points, mean; bars, SD. PU24FCl is a direct
Hsp90 binder that inhibits Hsp90 with a potency
comparable to the effect of YK5 on Hsp70 (Vilen-
chik et al., 2004).
(C) Growth inhibition: cancer cells were incubated
in triplicate with increasing concentrations of
YK5 and growth over 72 hr was assessed. HER2
degradation was analyzed as in (A), and gels were
quantified by densitometry. Recorded values were
normalized to control (vehicle-only treated cells)
and data graphed against YK5 concentration.
Error bars represent the SD of the mean (n = 3).
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Inactivating Hsp70 via an Allosteric Pocketproliferation (Figure 5C). Collectively, the concordance in the
observed biochemical (Figure 4B) and phenotypic (Figure 5)
effects observed with YK5 in cancer cells suggest that, in the
tested concentration range, the biological activity of YK5 is
majorly and selectively channeled through its Hsp70-binding
mechanism.
YK5 Alters the Hsp90/Hsp70 Machinery
We next investigated the mechanisms by which YK5 exerted its
biological activity. The function of the Hsp90 protein complex re-
quires the HSP-organizing protein (HOP), involved in the forma-
tion of the intermediate chaperone complex where client is
bound to both Hsp70 and Hsp90 and others, such as p23, that
act at the final or mature Hsp90 complex (Workman et al.,
2007). Treatment of cells with YK5 altered the formation of the
Hsp90-HOP-Hsp70 complex, but not the Hsp90-p23 complexes
(Figure 6A). This effect occurred at concentrations in accord with
its observed biological effect (compare Figure 6B with Figure 5).
It also resulted in onco-proteins release from Hsp90 (i.e., Raf-1;
Figure 6C) associated with a time-dependent reduction in
their steady-state levels (Figure 6D). Themechanism of degrada-
tion of these onco-proteins by YK5 was associated with protein
destabilization and cell clearance acceleration, as demon-
strated by reduced protein half-life (Figure 6E). Consistent with
a pathway of degradation via the proteasome, and further confir-
matory of an Hsp70/Hsp90 complex-mediated effect, inhibitors
of the proteasome but not of other proteolytic enzymes effi-
ciently rescued their degradation by YK5 (Figure 6F).
Collectively, these results indicate that the biological effects of
YK5 in cancer cells are, at least in part, mediated by altering the
formation of a functional Hsp90multi-chaperonemachinery (Fig-
ure 6G). When Hsp70 is inhibited by YK5, Hsp90 machinery1476 Chemistry & Biology 20, 1469–1480, December 19, 2013 ª2013onco-proteins cannot be transferred onto Hsp90, become
destabilized and targeted for clearance, at least in part by the
proteasome.
The Effect of YK5 on Hsp90 Is Uncoupled from HSF-1
The transcription factor heat shock factor-1 (HSF-1), the master
regulator of heat shock response, is another Hsp90 client, and
unlike onco-proteins, it becomes activated when Hsp90 is in-
hibited (Workman et al., 2007; Zou et al., 1998). HSF-1 activation
leads to a feedback increase in Hsp70 levels. Because, Hsp70 in
itself is a powerful anti-apoptotic molecule that inhibits both
intrinsic and extrinsic apoptotic pathways (Brodsky and Chiosis
2006; Re´role et al., 2011), this feedback response limits the po-
tency of Hsp90 inhibitors (Bagatell et al., 2000). In fact, the anti-
apoptotic function of Hsp70 is not limited to Hsp90 inhibitors,
and in general, Hsp70 protects cells from many other apoptotic
and necrotic stimuli (Daugaard et al., 2007; Re´role et al., 2011).
Feedback induction of Hsp70 was undetected with YK5 at
concentrations and in the time interval where we observed its
effects on Hsp90 onco-clients (Figure 7A). Meanwhile, in these
cells, direct Hsp90 inhibitors potently activated a heat shock
response, as evidenced by Hsp70 induction (Figure 7A;
PU24FCl).
We next investigated themechanism behind this effect. HSF-1
regulation by Hsp90 is mediated by formation of an Hsp90-HSF-
1 complex that maintains the transcription factor in a monomeric
state. Upon exposure of cells to an Hsp90 inhibitor, the chap-
erone dissociates from HSF-1, permitting it to trimerize, enter
the nucleus, and bind to heat shock response elements found
in the promoters of heat shock proteins, including Hsp70 (Zou
et al., 1998). YK5 had no effect on HSF-1 activation (Figure 7B).
Only heat shock and direct Hsp90 inhibitors (i.e., PU24FCl), butElsevier Ltd All rights reserved
Figure 6. Addition of YK5 to Cancer Cells Leads to Disruption of the Hsp90 Onco-Protein Regulating Machinery
(A–C) Cancer cells were treated for 24 hr with vehicle or indicated concentrations of YK5 (A and B) or for the indicated times with YK5 (C). Proteins isolated with
anti-Hsp90 and Hsp70s antibodies (IP: Hsp90 or Hsp70), or present in the cell extract (lysate) were analyzed with WB. Specificity of binding was tested with a
control IgG. HC, heavy chain. For (B), gels were quantified with densitometry and recorded values were normalized to control (vehicle-only treated cells) and data
were graphed against the YK5 concentration. Error bars represent the SD of the mean (n = 3).
(D) Representative WB of cancer cells treated for the indicated times with YK5. b-actin, loading control. This experiment was repeated twice with comparable
results.
(E) Cancer cells were treated for the indicated times with the protein biosynthesis inhibitor cycloheximide in the presence of vehicle (DMSO) or YK5 (10 mM).
Following WB analysis, protein expression was quantified by densitometry and graphed against time of treatment. Points, mean; bars, SD.
(F) Cancer cells were pretreated with the indicated proteolysis machinery inhibitors prior to addition of YK5 (10 mM). MG132 (Z-LL-CHO) and MG101 are pro-
teasome inhibitors. After 24 hr of treatment, protein expression in both detergent-soluble and insoluble fractions, in the presence (F) and absence of YK5 (not
shown) were analyzed with WB.
(G) Proposed mechanism of action for YK5 for altering the cancer-promoting Hsp90 machinery. The Hsp90 chaperoning cycle is a dynamic process in which
onco-client proteins are processed through an intermediate complex containing Hsp90, Hsp70, and HOP, leading to the conformational maturation of the onco-
protein, and cell proliferation and survival. YK5, by inhibiting Hsp70, interferes with the formation of a competent chaperone/onco-client complex, resulting in
onco-protein destabilization and its consequent clearance by the proteasome. This leads to cancer cell growth arrest and death.
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Inactivating Hsp70 via an Allosteric Pocketnot YK5, led to the formation of HSF-1 trimers, a process
required for HSF-1 activation and nuclear translocation. Poten-
tially as a consequence of this difference in their mechanism of
action, YK5, but not PU24FCl and PU-H71, led to substantial
apoptosis in these cells, as evidenced by cleavage of PARP (Fig-
ures 5A and 7A; cPARP).
These findings conclude that the onco-protein regulatory ac-
tion of the Hsp90machinery can be differentiated from its effects
on HSF-1 by upstream Hsp70 and Hsc70 inhibition by YK5. InChemistry & Biology 20, 1469–148this regard, YK5 becomes a chemical tool to study the biological
effect of Hsp90machinery inhibition in a chemical-HSF-1 knock-
down environment. The advantages of this intervention are
evident over the genetic manipulations of HSF-1, allowing for
temporal and spatial analysis of the cellular environment.
YK50s Binding Mode Is Distinct from That of Myricetin
We next investigated whether the phenotype observed with YK5
could be recapitulated with another Hsp70 binder, myricetin0, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1477
Figure 7. YK5 Leads to No HSF-1 Activation
or Feedback Heat Shock Response in
Cancer Cells
(A) Cancer cells were treated for 24 hr with vehicle
or indicated concentrations of inhibitors or for the
indicated times with YK5. Proteins were analyzed
with WB. b-actin, loading control. cPARP; cleaved
PARP. These experiments were repeated three
times with comparable results.
(B) Cancer cells were heat shocked for 45 min at
42C or incubated with vehicle, YK5, or PU24FCl
for 3 hr. Proteins were applied to a native gel and
analyzed with immunoblotting. This experiment
was repeated twice with comparable results.
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Inactivating Hsp70 via an Allosteric Pocket(Figure S6). This compound was recently reported to interact
with a site potentially adjacent to that occupied by YK5 (Chang
et al., 2011). In this report, myricetin binding to the E. coli
Hsp70, DnaK, a protein that lacks Cys267 (is Ala266 in DnaK),
was analyzed. Upon inspection of the proposed binding mode
of myricetin and YK5, we note that while there are a few residues
in common, the two agents are unlikely to occupy the same
pocket (Figure S6A). Several residues reported to affect binding
of myricetin to DnaK are more than 4 A˚ away from the site occu-
pied by YK5. Furthermore, myricetin effectively inhibited the
ATPase activity of DnaK (Chang et al., 2011) and the DJA2-stim-
ulated ATPase of Hsc70, unlike YK5 (Figures 4C and S6B). When
tested in several of our biochemical and cellular assays, myrice-
tin failed to mimic the phenotype we observe with YK5. Specif-
ically, although myricetin impaired in vitro luciferase refolding,
it had no effect on luciferase refolding activity in cells (Fig-
ure S6B), marginally altered the Hsp70-HOP complex in cells
(Figure S6C), and failed to degrade Raf-1 or induce apoptosis
in SKBr3 cells (Figure S6D). It is possible that for myricetin its
lack of activity in cells is due to a very low stability, as suggested
previously by others. Indeed, when we performed a time-depen-
dent analysis of this agent with LC/MS-MS, we could not detect
myricetin in cells as early as 10 min following its addition.
Altogether, these findings indicate that distinct Hsp70 inhibi-
tors may result in nonoverlapping phenotypes and underscore
the need for the discovery of Hsp70 ligands that act on the pro-
tein at discrete sites and/or through diverse mechanisms.
SIGNIFICANCE
Our study uncovers a therapeutically viable allostericbinding
site inhHsp70 thatallows for thedesignof apotentandselec-
tive inhibitor, YK5. This pocket and its interaction mode with
YK5 are not obvious nor entirely predicted by any of the avail-
able crystal structures, because they capture a binding
domain with the Cys267 unexposed to the solvent. We also
provide chemical tools, such as YK5 and a biotinylated YK5,1478 Chemistry & Biology 20, 1469–1480, December 19, 2013 ª2013 Elsevier Ltd All rights reto investigate Hsp70s in endogenous
cellular systems where the proteins
are limiting but not absent. We assem-
bled these chemical entities through
rational design. We believe these tools
will allow for the identification of novel
mechanisms for this therapeuticallyimportant chaperone protein and will provide valuable start-
ing points for the discovery of clinically relevant drugs that
act through such mechanism. While there is a concern that
an acrylamide entity could indiscriminately react with
nontarget-related proteins resulting in pleiotropic effects, in-
cubation of cells with YK5 concentrations five to ten times
higher than those needed to inhibit Hsp70 cellular activity in
cancer cells resulted selectively in the formation of YK5-
Hsp70 adducts. In addition, agents that result in unspecific
oxidation and labeling of cysteines are known to increase
cellular proteinmisfolding and to lead to consequent protec-
tive activation of a heat shock response, phenomenon not
observed with YK5. At the physiologically relevant concen-
tration of 10 mM (i.e., needed to maximally inhibit Hsp70-
cancer functions), YK5 was also inert when tested against
Ambit’s 402 kinase panel (G.C., unpublished data). Indeed,
further studies in this class demonstrated that reversible in-
hibitors designed around YK5 retained an Hsp70-mediated
mechanism, indicating that the acrylamide group could be
eliminated altogether by improving the enthalpy of the bind-
ing. These findingsconfirm that at the tested concentrations,
YK5 is a specific Hsp70 and Hsc70 dual modulator, and thus,
an appropriate tool to dissect the significance of pharmaco-
logic Hsp70s inhibition in cellular systems.
EXPERIMENTAL PROCEDURES
Reagents
We synthesized and characterized PU24FCl and PU-H71 as previously
described (He et al., 2006; Vilenchik et al., 2004). The synthesis and character-
ization of YK5 and YK5B is described elsewhere (Kang et al., 2012). We pur-
chased leupeptin, MG 132, MG 101, and PMSF from Sigma-Aldrich; AEBSF
from A.G. Scientific; and Z-VAD-FMK, BOC-D-FMK, cathepsin inhibitor 1,
and calpeptin from Calbiochem.
Buffers
We used high-salt buffer (20 mM Tris pH 7.4, 1 MNaCl, and 0.1%NP-40), low-
salt buffer (20 mM Tris pH 7.4, 25 mM NaCl, and 0.1% NP-40 buffer), or highserved
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Inactivating Hsp70 via an Allosteric Pocketsalt/high detergent (50 mM Tris, pH 7.4, 1% NP-40, 0.25% Na- deoxycholate,
1 M NaCl, and 1 mM EDTA) as indicated. To elute protein complexes from
YK5B-beads, we used, as indicated, either elution buffer A (62.5 mM TrisHCl
pH 6.8, 2% SDS, 10% glycerol, 15.5 mg/ml dithiothreitol, and bromophenol
blue 0.02 mg/ml) and boiled the sample at 100C for 3 min or elution buffer
B (2% SDS, 50 mM phosphate, 100 mM NaCl, 6 M urea, and 2 mM thiourea)
and incubated the sample for 15 min at room temperature, followed by 15 min
at 100C.
Cell Lines
SKBr3 cells were a gift from Dr. Neal Rosen, Memorial Sloan-Kettering Cancer
Center while K562 cells were obtained from American Type Culture Collection
andwerecultured routinely inDME/F12 (SKBr3)or inRPMI (K562) supplemented
with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin, and streptomycin.
Covalent Binding
K562 cells were treated with the indicated amount of YK5B for the indicated
time. Cells were collected and lysed in 20 mM Tris pH 7.4, 25 mM NaCl, and
0.1% NP-40 buffer. Cell extract (500 mg) in 100 ml of the lysis buffer was incu-
bated with streptavidin agarose beads for 1 hr at 4C. Samples were washed
five times with the lysis buffer or high salt (20 mM Tris pH 7.4, 1 M NaCl, and
0.1% NP-40) buffer and subjected to SDS-PAGE. Gels were silver stained
according to the manufacturer’s procedure (Invitrogen) or proteins were trans-
ferred onto nitrocellulose membrane followed by immunoblotting.
Chemical Precipitation
Protein lysates were prepared using 20 mM Tris pH 7.4, 25 mM NaCl, and
0.1% NP-40 lysis buffer. Streptavidin agarose beads (50 ml; Thermo Scientific)
were washed three times with lysis buffer, YK5B was added at the indicated
concentrations and the complexes were incubated at 4C for 1 hr. Upon a
three-time wash with buffer, beads were added to the indicated amount of to-
tal cellular protein in buffer. Samples were incubated at 4C overnight, washed
five times with the lysis buffer, and applied to SDS-PAGE.
Immunoprecipitation
Cells were collected and lysed in 20 mM Tris pH 7.4, 25 mM NaCl, and 0.1%
NP-40 buffer. Each sample contained 500 mg of a total protein. Appropriate
antibody (BB70 for Hsp70 and H9010 for Hsp90; 5 ml) or normal IgG (5 ml; as
a negative control) was added to each sample together with protein G agarose
beads (30 ml; Upstate) and incubated at 4C overnight. Samples were washed
five times with lysis buffer, and applied on SDS-PAGE followed by a standard
western blotting procedure.
Hsp70/HOP Complex Analysis
SKBr3 cells were treated with the indicated concentrations of the inhibitor for
24 hr. Samples were collected and lysed in 20 mM Tris pH 7.4, 25 mM NaCl,
and 0.1% NP-40 buffer with protease inhibitors added. Aliquots of 500 mg of
total protein adjusted to 100 ml with the lysis buffer were prepared. Samples
were incubated with 5 ml of BB70 antibody (Stressmarq) or normal IgG (as a
negative control) and 20 ml of protein G agarose beads (Upstate) at 4C over-
night. Samples were washed five times with the lysis buffer, and applied on
SDS-PAGE followed by a standard western blotting procedure to detect levels
of HOP protein in the Hsp/c70 complexes upon treatment.
More methods detailing analyses of proteasome-mediated degradation,
cycloheximide treatments, western blotting, native gel electrophoresis,
biochemical analyses of Hsp70 ATPase activity and luciferase refolding,
Hsp90 binding, and transfection studies are found in the Supplemental Exper-
imental Procedures.
Modeling
Computational studies were conducted using the Schroedinger Suite (http://
www.schrodinger.com). Details on the homology model building, binding
site prediction, and ligand docking techniques are summarized in the Supple-
mental Experimental Procedures.
Mass Spectrometry
Protein identification was performed by the Proteomics Core of MSKCC and
methods are detailed in the Supplemental Experimental Procedures.Chemistry & Biology 20, 1469–148SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Figures S1–S6, and Table S1 and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.10.008.
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